Acadian Asset Management LLC Buys Shares of 318,536 Mural Oncology plc (NASDAQ:MURA)

Acadian Asset Management LLC bought a new stake in Mural Oncology plc (NASDAQ:MURA) in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 318,536 shares of the company’s stock, valued at approximately $998,000. Acadian Asset Management LLC owned 1.88% of Mural Oncology at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. BBR Partners LLC acquired a new position in Mural Oncology in the second quarter valued at about $31,000. Rhumbline Advisers acquired a new position in shares of Mural Oncology during the second quarter worth about $34,000. Finally, Harbor Capital Advisors Inc. acquired a new position in shares of Mural Oncology during the second quarter worth about $115,000. 80.21% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Rodman & Renshaw initiated coverage on shares of Mural Oncology in a research note on Friday, June 28th. They set a “buy” rating and a $15.00 price target for the company.

Insider Transactions at Mural Oncology

In other Mural Oncology news, CEO Caroline Loew sold 12,531 shares of the company’s stock in a transaction on Monday, July 8th. The shares were sold at an average price of $2.91, for a total transaction of $36,465.21. Following the sale, the chief executive officer now directly owns 240,391 shares of the company’s stock, valued at $699,537.81. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 0.06% of the company’s stock.

Mural Oncology Stock Down 1.5 %

Shares of MURA opened at $3.24 on Tuesday. Mural Oncology plc has a twelve month low of $2.88 and a twelve month high of $17.00. The company has a 50 day moving average of $3.28 and a 200-day moving average of $3.71.

Mural Oncology (NASDAQ:MURA) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($1.86) earnings per share for the quarter, topping the consensus estimate of ($1.90) by $0.04. On average, sell-side analysts predict that Mural Oncology plc will post -7.54 EPS for the current fiscal year.

Mural Oncology Company Profile

Mural Oncology plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab.